Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
Date:2/21/2013

THE WOODLANDS, Texas, Feb. 21, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2012.

"We continued to make significant progress in the development of our pipeline in 2012, highlighted by positive results from clinical studies of LX4211 in diabetes and telotristat etiprate in carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "We are pleased to have commenced the Phase 3 program for telotristat etiprate in carcinoid syndrome, and continue to progress in our preparations for LX4211 Phase 3 initiation. We also look forward to significant proof-of-concept results in irritable bowel syndrome (IBS) with LX1033, ulcerative colitis with telotristat etiprate, and type 1 diabetes with LX4211 in 2013."

Key Developments in 2012

  • LX4211:  Lexicon reported positive results from a 12-week Phase 2b clinical trial of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) in patients with type 2 diabetes who were concurrently treated with metformin, an established diabetes therapy. LX4211 treatment produced substantial, dose-dependent and statistically-significant reductions in hemoglobin A1c (HbA1c), with patients in the high dose (400 mg QD) LX4211 treatment arm having a mean HbA1C reduction from baseline of 0.95 percent (p<0.001). In patients randomized to placebo, HbA1C decreased by 0.09 percent. LX4211 treatment also produced significant reduct
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon To Present At The BIO CEO & Investor Conference
    2. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
    3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
    4. Lexicon to Provide Third Quarter 2012 Financial Results
    5. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
    6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    7. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    9. Lexicon to Provide Second Quarter 2012 Financial Results
    10. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    11. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
    (Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
    (Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
    Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
    ... 19 Celsion Corporation (Nasdaq: CLSN ... ThermoDox® High Intensity Focused Ultrasound (HIFU) development program ... MR-guided Focused Ultrasound 2010 2nd International Symposium.  The ... as the rationale and support for future clinical ...
    ... Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi ... reduce significantly deleterious side effects triggered by conventional ... operations. The company is currently developing a novel ... on its asymmetric shorter-duplex siRNA (asiRNA) technology, originally ...
    Cached Medicine Technology:Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 2Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium 3BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 2BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors 3
    (Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
    (Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
    (Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
    (Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
    (Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
    Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
    ... Rehabilitation Research and Development (JRRD) mainly analyses articles related ... sexuality, chronic pain and prosthetics research. ,Under ... pain associated with spinal cord injury the author of ... cord injury) reported chronic pain. He inquired about their ...
    ... are said to account for a large portion of ... to assess// this assumption in the Arab world. ... WHO World Mental Health (WMH) Survey Initiative, a nationally ... in Lebanon between September, 2002, and September, 2003, through ...
    ... School of Veterinary Medicine have established a national ... to humans and animals using medical records of ... Professor of Epidemiology. Larry Glickman of the School ... Pet Hospital, a nationwide chain of veterinary hospitals ...
    ... Pete Burns, following complaints of "sleep deprivation and exhaustion", has ... ,Burns, who is 46, had been residing at ... expensive pounds 450-a-night. There has been gossip doing the rounds ... the star out of his room for not paying his ...
    ... study by the New England Research Institutes in collaboration with ... or too little// are at a greater risk of developing ... based on studies done on over 1709 men, in the ... a period of 15 yrs. ,According to the ...
    ... A novel study conducted by Columbia University Medical ... for use in osteoarthritis, could be effective// in ... Until now, drug treatment with Cox-2 inhibitors or ... patients with chronic shoulder pain. ,Approximately ...
    Cached Medicine News:Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 2Health News:JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics 3Health News:A National Survey Revealed That Mental Disorders Are Common In Lebanon 2Health News:Pets As Disease Watchdogs 2Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2
    ... Oxyflo is a highly featured laser ... microvascular blood perfusion from multiple tissue ... developments in Digital Signal Processing (DSP) ... technologically advanced, yet simple to use, ...
    ... a highly featured laser doppler system ... perfusion from multiple tissue sites. This ... Digital Signal Processing (DSP) and laser ... yet simple to use, multi-channel monitor, ...
    Transcranial vascular DWL doppler....
    The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
    Medicine Products: